Artigo Produção Nacional Revisado por pares

Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells

2017; Bentham Science Publishers; Volume: 17; Issue: 9 Linguagem: Inglês

10.2174/1871520617666170213112904

ISSN

1875-5992

Autores

Julia Alejandra Pezuk, María Sol Brassesco, Priscila Maria Manzini Ramos, Carlos Alberto Scrideli, Luíz Gonzaga Tone,

Tópico(s)

Neuroblastoma Research and Treatments

Resumo

Background: Medulloblastoma (MB) is one of most frequent malignant tumors that affect children. Despite the relatively good survival rate, long time sequels still represent a challenge for MB. Therefore, in an attempt to reduce treatment aftereffects, new therapeutic targets are constantly being explored. Polo like kinase 1 (PLK1) is a master cell cycle regulator that is increased in proliferative cells, while its depletion has been repeatedly proposed as an oncological therapeutic strategy. Keywords: Medulloblastoma, PLK1 inhibition, BI 2536, BI 6727, GW843682X, GSK461364.

Referência(s)